Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jul;22(7):903-905.
doi: 10.1016/S1470-2045(21)00303-X. Epub 2021 Jun 15.

Immunotherapy in ovarian cancer: we are not there yet

Emma Barber  1 , Daniela Matei  2
Affiliations
Comment

Immunotherapy in ovarian cancer: we are not there yet

Emma Barber et al. Lancet Oncol. 2021 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

We declare no competing interests.

Comment on

References

    1. Disis ML, Taylor MH, Kelly K, et al. Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial. JAMA Oncol 2019; 5: 393–401. - PMC - PubMed
    1. Varga A, Piha-Paul S, Ott PA, et al. Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: analysis of KEYNOTE-028. Gynecol Oncol 2019; 152: 243–50. - PubMed
    1. Shu CA, Gainor JF, Awad MM, et al. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol 2020; 21: 786–95. - PubMed
    1. Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 2018; 378: 2078–92. - PubMed
    1. Pujade-Lauraine E, Fujiwara K, Ledermann JA, et al. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, parallel-group, three-arm, randomised, phase 3 study. Lancet Oncol 2021; published online June 15. 10.1016/S1470-2045(21)00216-3 - DOI - PubMed

LinkOut - more resources